{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:46:28Z","timestamp":1791240388207,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1038\/s41416-018-0168-9","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T11:38:51Z","timestamp":1530617931000},"page":"193-199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy"],"prefix":"10.1038","volume":"119","author":[{"given":"Frantz","family":"Dupuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Lamant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Gerard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouritza","family":"Torossian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Chaltiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Filleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Beylot-Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorilla","family":"Prey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Jullie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Vergier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,5]]},"reference":[{"key":"168_CR1","first-page":"1280","volume":"14","author":"JR Thumar","year":"2010","unstructured":"Thumar, J. R. & Kluger, H. M. Ipilimumab: a promising immunotherapy for melanoma. Oncol. Williston Park 14, 1280\u20131288 (2010).","journal-title":"Oncol. Williston Park"},{"key":"168_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"1","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 1, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"168_CR3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"8","author":"A Ribas","year":"2015","unstructured":"Ribas, A. et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 8, 908\u2013918 (2015).","journal-title":"Lancet Oncol."},{"key":"168_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"4","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 4, 320\u2013330 (2015).","journal-title":"N. Engl. J. Med."},{"key":"168_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"4","author":"JS Weber","year":"2015","unstructured":"Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 4, 375\u2013384 (2015).","journal-title":"Lancet Oncol."},{"key":"168_CR6","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"26","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 26, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"168_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"2","author":"O Hamid","year":"2013","unstructured":"Hamid, O. et al. Safety and tumour responses with lambrolizumab (Anti\u2013PD-1) in melanoma. N. Engl. J. Med. 2, 134\u2013144 (2013).","journal-title":"N. Engl. J. Med."},{"key":"168_CR8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2217\/imt-2016-0025","volume":"9","author":"O Abdel-Rahman","year":"2016","unstructured":"Abdel-Rahman, O. PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1\/PD-L1 agents: a meta-analysis. Immunotherapy 9, 1081\u20131089 (2016).","journal-title":"Immunotherapy"},{"key":"168_CR9","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","volume":"4","author":"KM Mahoney","year":"2015","unstructured":"Mahoney, K. M., Freeman, G. J. & McDermott, D. F. The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma. Clin. Ther. 4, 764\u2013782 (2015).","journal-title":"Clin. Ther."},{"key":"168_CR10","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"19","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N. Engl. J. Med. 19, 1823\u20131833 (2016).","journal-title":"N. Engl. J. Med."},{"key":"168_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00428-016-1910-4","volume":"5","author":"M Ilie","year":"2016","unstructured":"Ilie, M., Hofman, V., Dietel, M., Soria, J.-C. & Hofman, P. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. Int J. Pathol. 5, 511\u2013525 (2016).","journal-title":"Virchows Arch. Int J. Pathol."},{"key":"168_CR12","first-page":"74","volume":"2","author":"M Santarpia","year":"2015","unstructured":"Santarpia, M. & Karachaliou, N. Tumour immune microenvironment characterization and response to anti-PD-1 therapy. Cancer Biol. Med. 2, 74\u201378 (2015).","journal-title":"Cancer Biol. Med."},{"key":"168_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/pcmr.12340","volume":"3","author":"J Madore","year":"2015","unstructured":"Madore, J. et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L1 clinical trials. Pigment. Cell. Melanoma Res. 3, 245\u2013253 (2015).","journal-title":"Pigment. Cell. Melanoma Res."},{"key":"168_CR14","unstructured":"Guo Q., et al. New mechanisms of tumour-associated macrophages on promoting tumour progression: recent research advances and potential targets for tumour immunotherapy. J. Immunol. Res. 2016, 9720912 (2016)."},{"key":"168_CR15","doi-asserted-by":"publisher","first-page":"9002","DOI":"10.1200\/jco.2014.32.15_suppl.9002","volume":"15","author":"FS Hodi","year":"2014","unstructured":"Hodi, F. S. et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J. Clin. Oncol. 15, 9002\u20139002 (2014).","journal-title":"J. Clin. Oncol."},{"key":"168_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","volume":"100","author":"S Gandini","year":"2016","unstructured":"Gandini, S., Massi, D. & Mandal\u00e0, M. PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 100, 88\u201398 (2016).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"168_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/978-1-62703-727-3_16","volume":"1102","author":"T Schatton","year":"2014","unstructured":"Schatton, T., Scolyer, R. A., Thompson, J. F. & Mihm, M. C. Tumour-infiltrating lymphocytes and their significance in melanoma prognosis. Methods Mol. Biol. Clifton NJ 1102, 287\u2013324 (2014).","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"168_CR18","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"11","author":"MWL Teng","year":"2015","unstructured":"Teng, M. W. L., Ngiow, S. F., Ribas, A. & Smyth, M. J. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 11, 2139\u20132145 (2015).","journal-title":"Cancer Res."},{"key":"168_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0207","volume":"3","author":"DB Johnson","year":"2015","unstructured":"Johnson, D. B. et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol. Res 3, 288\u2013295 (2015).","journal-title":"Cancer Immunol. Res"},{"key":"168_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","volume":"10","author":"L Yang","year":"2017","unstructured":"Yang, L. & Zhang, Y. Tumour-associated macrophages: from basic research to clinical application. J. Hematol. Oncol. 10, 58 (2017).","journal-title":"J. Hematol. Oncol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0168-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0168-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0168-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:46Z","timestamp":1684616566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0168-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["168"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0168-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"14 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in accordance with the Declaration of Helsinki. All patients provided written informed consent for the use of the samples, and the local Ethics Committee approved the study. (Ethic Committee of the university hospital of Bordeaux, reference of the case GP-CE-2018\/02 attached in the cover letter).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All data supporting the results reported in the article can be found in departments of Pathology of Bordeaux hospital (CHU) and Toulouse Oncopole.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"The authors declare no funding or sponsorship (e.g. university, charity, commercial organization) for this study. Immunohistochemical technics were performed in the departments of pathology (CHU Bordeaux and Oncopole Toulouse).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}